

CLINICAL TRIAL

REVERSE - NCT02652780

Neuroophthalmology RED



Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation

Rare Eye Disease concerned by the trial :
Leber hereditary optic neuropathy (LHON)

Status of the trial : completed

Orphan drug recognition : No

Inclusion criteria : Patients with Leber hereditary optic neuropathy (LHON) carrying the m.11778G>A mitochondrial DNA mutation carrying the m.11778G>A mitochondrial DNA mutation

Exclusion criteria : Disease duration of more than one year in one or both eyes



Inclusion opening date : 01/02/2016



Inclusion closing date : 01/08/2017

Children



Adults



Within ERN-EYE members



Principal location of the trial :

Moorfields Eye Hospital

City Road
London, EC1V 2PD
UK

[Contact details](#)



Principal investigator name :

Patrick Yu-Wai-Man




Other investigators :

Catherine Vignal

CHNO des XV XX

28 rue de Charenton
75012 Paris
France



Funder type : Drug company - Industry

[More informations](#)